FrancophonIA/ELRC3.0 huggingface dataset:
English: 16% had a Karnofsky Performance Status of 100; 42% had a KPS of 90; 35% had a KPS of 80; 7% had a KPS of 70; and <1% of patients had a KPS of below 70.
Croatian: U 16% funkcionalni status prema Karnofskyju (KPS) iznosio je 100; 42% imalo je KPS od 90; 35% KPS od 80; 7% KPS od 70; a < 1% bolesnika imalo je KPS manji od 70.
English: Abraxane should not be used in pregnancy, and in women of childbearing potential not using effective contraception, unless the clinical condition of the mother requires treatment with paclitaxel.
Croatian: Abraxane se ne smije primjenjivati tijekom trudnoće kao ni u žena reproduktivne dobi koje ne koriste učinkovitu kontracepciju, osim ako kliničko stanje trudnice ne zahtijeva liječenje paklitakselom.
English: Because of potential serious adverse reactions in breast-feeding infants, Abraxane is contraindicated during lactation.
Croatian: S obzirom na moguće ozbiljne nuspojave u dojenčadi, Abraxane je kontraindiciran tijekom laktacije.
English: Abraxane is supplied as a sterile lyophilised powder for reconstitution before use.
Croatian: Abraxane se isporučuje kao sterilni liofilizirani prašak za rekonstituciju prije uporabe.
English: Abraxane has minor or moderate influence on the ability to drive and use machines.
Croatian: Abraxane malo ili umjereno utječe na sposobnost upravljanja vozilima i rada sa strojevima.
English: For patients of 75 years and older, no benefit for the combination treatment of Abraxane and gemcitabine in comparison to gemcitabine monotherapy has been demonstrated.
Croatian: Za bolesnike u dobi od 75 i više godina, nije dokazana korist od liječenja kombinacijom Abraxanea i gemcitabina u usporedbi s monoterapijom gemcitabina.
English: Do not administer the reconstituted suspension if particulate matter is observed in the vial.
Croatian: Nemojte primijeniti rekonstituiranu suspenziju ako u bočici primijetite strane čestice.
English: Because these events have been reported voluntarily during clinical practice, true estimates of frequency cannot be made and a causal relationship to the events has not been established.
Croatian: Budući da su ti događaji zabilježeni spontano tijekom kliničke prakse, nije bilo moguće uspostaviti uzročnu povezanost s događajima te procijeniti stvarnu učestalost.
English: The use of medical devices containing silicone oil as a lubricant (i.e. syringes and IV bags) to reconstitute and administer Abraxane may result in the formation of proteinaceous strands.
Croatian: Uporaba medicinskih proizvoda koje sadrže silikonsko ulje kao lubrikant (tj. štrcaljke i intravenske vrećice) za rekonstituciju i primjenu lijeka Abraxane može rezultirati stvaranjem proteinskih vlakana.
English: The paclitaxel exposure (AUC) increased linearly from 2653 to 16736 ng.hr/ml following dosing from 80 to 300 mg/m2.
Croatian: Izloženost paklitakselu (AUC) povećavala se linearno s 2653 na 16 736 ng.h/ml nakon primjenjivanih doza od 80 do 300 mg/m2.
English: • Abnormal decrease in the number of types of white blood cells (neutrophils, lymphocytes or leukocytes) in the blood
Croatian: • abnormalno smanjenje broja vrsta bijelih krvnih stanica (neutrofila, limfocita ili leukocita) u krvi
English: For treatment of metastatic breast cancer, Abraxane is usually given once every three weeks (on day 1 of a 21-day cycle).
Croatian: Za liječenje metastatskog raka dojke, Abraxane se obično daje jednom svaka tri tjedna (1. dana svakog 21-dnevnog ciklusa).
English: Paclitaxel at doses below the human therapeutic dose was associated with low fertility when administered prior and during mating in male and female rats and foetal toxicity in rats.
Croatian: Paklitaksel u dozama nižim od terapijskih doza za čovjeka povezuje se s niskom plodnošću kada se primjenjuje prije i tijekom parenja u mužjaka i ženki štakora i s fetalnom toksičnošću u štakora.
English: Pharmacokinetic interactions between Abraxane and gemcitabine have not been evaluated in humans.
Croatian: Farmakokinetičke interakcije između Abraxanea i gemcitabina nisu procijenjene u ljudi.
English: • if you experience any abnormal bruising, bleeding, or signs of infections such as a sore throat or a fever;
Croatian: • ako opazite abnormalnu pojavu modrica, krvarenja ili znakove infekcija kao što su grlobolja ili vrućica;
English: Unopened vials of Abraxane are stable until the date indicated on the package when the vial is kept in the outer carton in order to protect from light.
Croatian: Neotvorene bočice lijeka Abraxane stabilne su do datuma naznačenog na pakiranju kada se bočica čuva u vanjskom pakiranju radi zaštite od svjetlosti.
English: • if you have a low white blood cell count (baseline neutrophil counts <1500 cells/mm3 - your doctor will advise you on this).
Croatian: • ako imate nizak broj leukocita (početni broj neutrofila < 1500 stanica/mm3 - liječnik će Vas savjetovati o tome).
English: Taking into account the PRAC Assessment Report on the PSUR(s) for paclitaxel albumin, the scientific conclusions of CHMP are as follows:
Croatian: Uzimajući u obzir PRAC-ovo izvješće o ocjeni periodičkog(ih) izvješća o neškodljivosti lijeka (PSUR) za paklitaksel albumin, znanstveni zaključci CHMP-a su sljedeći:
English: The exact total dosing volume of 5 mg/ml suspension required for the patient should be calculated and the appropriate amount of reconstituted Abraxane should be injected into an empty, sterile, PVC or non-PVC type intravenous bag.
Croatian: Treba izračunati točan ukupni volumen doziranja suspenzije od 5 mg/ml potreban za bolesnika i odgovarajuću količinu rekonstituiranog lijeka Abraxane ubrizgati u praznu, sterilnu, PVC ili ne-PVC vrećicu za intravensku infuziju.
English: Although limited data is available, no clear benefit in terms of prolonged overall survival has been demonstrated in pancreatic adenocarcinoma patients with normal CA 19-9 levels prior to start of treatment with Abraxane and gemcitabine (see section 5.1).
Croatian: Iako postoje ograničeni podaci, nije dokazana jasna korist s obzirom na produljeno opće preživljenje u bolesnika s adenokarcinomom pankreasa i normalnim razinama CA 19-9 prije početka terapije lijekom Abraxane i gemcitabinom (vidjeti dio 5.1).
English: The fraction of free paclitaxel was significantly higher with Abraxane (6.2%) than with solvent-based paclitaxel (2.3%).
Croatian: Frakcija slobodnog paklitaksela bila je znatno veća s lijekom Abraxane (6,2%) nego s paklitakselom baziranom na otapalu (2,3%).
English: Treatment should be directed at the major anticipated toxicities, which are bone marrow suppression, mucositis and peripheral neuropathy.
Croatian: Liječenje treba usmjeriti na glavne očekivane toksičnosti kao što su supresija koštane srži, mukozitis i periferna neuropatija.
English: What Abraxane is used for Abraxane is used to treat the following types of cancer:
Croatian: Za što se Abraxane koristi Abraxane se koristi za liječenje ovih vrsta raka:
English: Proporti on of
Croatian: Pro po rti on of
English: This medicine has not been studied in children and adolescents, as breast cancer, pancreatic cancer and lung cancer do not occur in these age groups.
Croatian: Ovaj lijek nije ispitan u djece i adolescenata jer se karcinom dojke, rak gušterače i rak pluća ne javljaju u tim dobnim skupinama.
English: Paclitaxel has been shown to be genotoxic in vivo (micronucleus test in mice), but it did not induce mutagenicity in the Ames test or the Chinese hamster ovary/hypoxanthine-guanine phosphoribosyl transferase (CHO/HGPRT) gene mutation assay.
Croatian: Paklitaksel se pokazao genotoksičnim u uvjetima in vivo (test mikrojezgre na miševima), ali nije uzrokovao mutagenost u Amesovom testu ili testu mutacije gena jajnika kineskog hrčka/hipoksantin-gvanin fosforibozil transferaze (CHO/HGPRT).
English: Your doctor will arrange a pregnancy test before starting treatment with Abraxane.
Croatian: Vaš će liječnik dogovoriti testiranje na trudnoću prije početka liječenja lijekom Abraxane.
English: Grade 4 neutropenia (< 500 cells/mm3) occurred in 9% of patients treated with Abraxane.
Croatian: Neutropenija 4. stupnja (< 500 stanica/mm3) javila se u 9% bolesnika liječenih lijekom Abraxane.
English: Response rate [95% CI] (%)
Croatian: Stopa odgovora [95% CI] (%)
English: • medicines for treating infections (i.e. antibiotics such erythromycin, rifampicin, etc.; ask your doctor, nurse or pharmacist if you are unsure whether the medicine you are taking is an antibiotic),
Croatian: • lijekovi za liječenje infekcija (tj. antibiotici kao što su eritromicin, rifampicin, itd.; provjerite s liječnikom, medicinskom sestrom ili ljekarnikom ako niste sigurni je li lijek koji uzimate antibiotik), uključujući lijekove za liječenje gljivičnih infekcija (npr. ketokonazol)
English: • Decreased blood pressure when standing up, coldness in your hands and feet
Croatian: • sniženi krvni tlak prilikom ustajanja, hladnoća šaka i stopala
English: Treatment effects on OS favoured the Abraxane/gemcitabine arm across the majority of pre-specified subgroups (including gender, KPS, geographic region, primary location of pancreatic cancer, stage at diagnosis, presence of liver metastases, presence of peritoneal carcinomatosis, prior Whipple procedure, presence of biliary stent at baseline, presence of pulmonary metastases, and number of metastatic sites).
Croatian: Učinci liječenja na sveukupno preživljenje bili su u prilog skupine koja je primala Abraxane/gemcitabin u većini unaprijed određenih podskupina (uključujući spol, KPS, zemljopisnu regiju, primarno mjesto karcinoma pankreasa, stadij prilikom dijagnoze, prisutnost metastaza jetre, prisutnost peritonejske karcinomatoze, prethodni Whippleov postupak, prisutnost bilijarnog stenta na početku, prisutnost plućnih metastaza i broj metastaznih mjesta).
English: On the basis of the scientific conclusions for paclitaxel albumin the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing paclitaxel albumin is unchanged subject to the proposed changes to the product information
Croatian: Na temelju znanstvenih zaključaka za paklitaksel albumin, CHMP smatra da je omjer koristi i rizika lijeka(ova) koji sadrži(e) paklitaksel albumin nepromijenjen, uz predložene izmjene informacija o lijeku.
English: Based on non-compartmental PK analysis, the plasma clearance of paclitaxel with Abraxane was larger (43%) than that following a solvent-based paclitaxel injection and its volume of distribution was also higher (53%).
Croatian: Na temelju farmakokinetičke analize bez uključivanja odjeljaka, plazmatski klirens paklitaksela s lijekom Abraxane bio je veći (43%) nego nakon primjene injekcija paklitaksela baziranog na otapalu, a i njegov volumen distribucije bio je također veći (53%).
English: Patient-reported taxane toxicity was assessed using the 4 subscales of the Functional Assessment of Cancer Therapy (FACT)-Taxane questionnaire.
Croatian: Toksičnost povezana s taksanom prema samoprocjeni bolesnika dobivena je na temelju 4 podljestvice upitnika za funkcionalnu procjenu terapije karcinoma taksanom (Functional Assessment of Cancer Therapy (FACT) - Taxane).
English: There was no difference in ORR between the treatment arms in patients with non-squamous histology (N=602, 26% vs 25%, p=0.808).
Croatian: Nije bilo razlike u stopi sveukupnog odgovora između terapijskih skupina u bolesnika s histološkim tipom neskvamoznih stanica (N = 602, 26% naspram 25%, p = 0,808).
English: This resulted in significantly higher exposure to unbound paclitaxel with Abraxane compared with solvent-based paclitaxel, even though the total exposure is comparable.
Croatian: To je rezultiralo značajno većom izloženošću nevezanom paklitakselu s lijekom Abraxane u usporedbi s paklitakselom baziranom na otapalu, iako je ukupna izloženost usporediva.
English: Nausea occurred in 29% of the patients and diarrhoea in 25% of the patients.
Croatian: Mučnina se javila u 29% bolesnika, a proljev u 25% bolesnika.
English: The most common clinically significant adverse reactions associated with the use of Abraxane have been neutropenia, peripheral neuropathy, arthralgia/myalgia and gastrointestinal disorders.
Croatian: Najčešće klinički značajne nuspojave povezane s primjenom lijeka Abraxane bile su neutropenija, periferna neuropatija, artralgija/mijalgija i gastrointestinalni poremećaji.
English: The key secondary endpoints were progressionfree survival (PFS) and overall response rate (ORR), both assessed by independent, central, blinded radiological review using RECIST guidelines (Version 1.0).
Croatian: Ključni sekundarni ishodi bili su preživljenje bez progresije bolesti (PFS) i stopa sveukupnog odgovora (ORR), a oba ishoda procijenjena su neovisnom, centralnom, maskiranom radiološkom procjenom na temelju smjernica RECIST (verzija 1.0).
English: Patients in the Abraxane/carboplatin arm had a significantly higher overall response rate compared with patients in the control arm: 33% versus 25%, p = 0.005 (Table 12).
Croatian: Bolesnici u skupini Abraxane/karboplatin imali su značajno višu ukupnu stopu odgovora u usporedbi s kontrolnom skupinom: 33% naspram 25%, p = 0,005 (tablica 12).
English: • Abraxane is used in non-small cell lung cancer where surgery or radiotherapy would not be suitable to treat the disease.
Croatian: • Abraxane se koristi za liječenje karcinoma nemalih stanica pluća kada kirurški zahvat ili radioterapija ne bi bili pogodni za liječenje bolesti.
English: Do not use this medicine after the expiry date which is stated on the carton and the vial after EXP.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i bočici iza oznake „EXP“.
English: ANNEX IV Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)
Croatian: PRILOG IV. Znanstveni zaključci i razlozi za izmjenu uvjeta odobrenja za stavljanje lijeka u promet
English: • a medicine called clopidogrel used to prevent blood clots.
Croatian: • lijek pod nazivom klopidogrel koji se koristi za sprječavanje stvaranja krvnih ugrušaka.
English: • Abraxane is also used together with a medicine called carboplatin if you have the most common type of lung cancer, called “non-small cell lung cancer”.
Croatian: • Abraxane se također koristi s lijekom pod nazivom karboplatin ako imate najčešći oblik raka pluća koji se naziva “karcinom nemalih stanica pluća”.
English: The total combined storage time of reconstituted medicinal product in the vial and in the infusion bag when refrigerated and protected from light is 24 hours.
Croatian: Ukupno vrijeme kombiniranog čuvanja rekonstituiranog lijeka u bočici i vrećici za infuziju kada se čuva u hladnjaku uz zaštitu od svjetlosti iznosi 24 sata.
English: Abraxane contains, as its active substance, paclitaxel attached to the human protein albumin, in the form of tiny particles known as nanoparticles.
Croatian: Kao djelatnu tvar Abraxane sadrži paklitaksel vezan na ljudski protein albumin u obliku sićušnih čestica poznatih kao nanočestice.
English: Male patients treated with Abraxane are advised to use effective contraception and to avoid fathering a child during and up to six months after treatment.
Croatian: Muškim bolesnicima liječenim lijekom Abraxane savjetuje se da koriste učinkovitu kontracepciju i da izbjegavaju začeće djeteta tijekom i do šest mjeseci nakon završetka liječenja.
English: Peripheral Neuropathy: Grade 3 or 4
Croatian: Periferna neuropatija: 3. ili 4. stupnja
English: The majority of alopecia events occurred less than one month after initiation of Abraxane.
Croatian: Alopecija se većinom pojavila u razdoblju kraćem od mjesec dana nakon početka primjene lijeka Abraxane.
English: Albumin is known to mediate endothelial caveolar transcytosis of plasma constituents, and in vitro studies demonstrated that the presence of albumin in Abraxane enhances transport of paclitaxel across endothelial cells.
Croatian: Poznato je da albumin posreduje u endotelnoj kaveolarnoj transcitozi sastojaka plazme, a in vitro ispitivanja pokazala su da prisutnost albumina u lijeku Abraxane povećava prijenos paklitaksela kroz endotelne stanice.
English: People with metastatic pancreatic cancer (pancreatic cancer that has spread to other parts of the body) who received Abraxane with gemcitabine in a clinical trial lived longer than people who had only received gemcitabine.
Croatian: Osobe s metastatskim rakom gušterače (rak gušterače koji se proširio na druge dijelove tijela), a koji su primali Abraxane s gemcitabinom u kliničkom ispitivanju, živjeli su dulje od onih koji su primali samo gemcitabin.
English: In a repeat dose study with 12 patients receiving Abraxane administered intravenously at 260 mg/m2, intrapatient variability in AUC was 19% (range = 3.21%-37.70%).
Croatian: U ispitivanjima ponovljene doze s 12 bolesnika koji su primali Abraxane intravenski u dozi od 260 mg/m2, varijabilnost između bolesnika u vrijednosti AUC-a iznosila je 19% (raspon = 3,21%37,70%).
English: There were no clinically relevant pharmacokinetic interactions between Abraxane and carboplatin.
Croatian: Nije bilo klinički važnih farmakokinetičkih interakcija lijeka Abraxane i karboplatina.
English: What Abraxane contains
Croatian: Što Abraxane sadrži
English: Rare: Radiation recall phenomenon, radiation pneumonitis
Croatian: Rijetko: pojava recidiva kožnih reakcija izazvanih zračenjem, radijacijski pneumonitis
English: Febrile Neutropenia: Grade 3 or 4
Croatian: Febrilna neutropenija: 3. ili 4. stupnja
English: Therefore, in the absence of a PK drug-drug interaction study, caution should be exercised when administering paclitaxel concomitantly with medicines known to inhibit either CYP2C8 or CYP3A4 (e.g. ketoconazole and other imidazole antifungals, erythromycin, fluoxetine, gemfibrozil, clopidogrel, cimetidine, ritonavir, saquinavir, indinavir, and nelfinavir) because toxicity of paclitaxel may be increased due to higher paclitaxel exposure.
Croatian: Stoga budući da nije provedeno farmakokinetičko ispitivanje interakcije lijekova, potreban je oprez prilikom primjene paklitaksela istodobno s lijekovima za koje je utvrđeno da inhibiraju bilo CYP2C8 ili CYP3A4 (primjerice, ketokonazol i drugi imidazolni antifungici, eritromicin, fluoksetin, gemfibrozil, klopidogrel, cimetidin, ritonavir, sakvinavir, indinavir i nelfinavir) jer toksičnost paklitaksela može biti povećana usljed veće izloženosti paklitakselu.
English: In this phase III randomized, controlled, open-label trial, adverse reactions resulting in death within 30 days of the last dose of study drug were reported for 4% of patients receiving Abraxane in combination with gemcitabine and for 4% of patients receiving gemcitabine monotherapy.
Croatian: U ovom randomiziranom, kontroliranom, otvorenom ispitivanju faze III, nuspojave koje su rezultirale smrću unutar 30 dana od zadnje doze ispitivanog lijeka zabilježene su u 4% bolesnika koji su primali Abraxane u kombinaciji s gemcitabinom i 4% bolesnika koji su primali gemcitabin kao monoterapiju.
English: • medicines used to treat HIV and AIDS (e.g. ritonavir, saquinavir, indinavir, nelfinavir, efavirenz,
Croatian: • lijekovi za liječenje HIV-a i SIDA-e (npr. ritonavir, sakvinavir, indinavir, nelfinavir, efavirenz,
English: Pharmacokinetic data are insufficient for patients with severe renal impairment and not available for patients with end stage kidney disease.
Croatian: Farmakokinetički podaci o bolesnicima s teškim oštećenjem bubrežne funkcije nisu dostatni, a nema ih za bolesnike s krajnjim stadijem bubrežne bolesti.
English: Anaemiaa,b Neutropenia a,b Thrombocytopeniab,c a 405 patients assessed in Abraxane/gemcitabine-treated group b 388 patients assessed in gemcitabine-treated group c 404 patients assessed in Abraxane/gemcitabine-treated group
Croatian: Anemijaa,b Neutropenijaa,b Trombocitopenijab,c a 405 bolesnika procijenjeno u skupini liječenoj Abraxaneom/gemcitabinom b 388 bolesnika procijenjeno u skupini liječenoj gemcitabinom c 404 bolesnika procijenjeno u skupini liječenoj Abraxaneom/gemcitabinom
English: Patients with pancreatic adenocarcinoma aged 75 years and older should be carefully assessed before treatment is considered (see section 4.4).
Croatian: Bolesnike s adenokarcinomom pankreasa u dobi od 75 i više godina valja pažljivo procijeniti prije nego što se razmatra liječenje (vidjeti dio 4.4).
English: Of the 431 patients with pancreatic adenocarcinoma who were randomized to receive Abraxane in combination with gemcitabine, the majority (93%) were white, 4% were black and 2% were Asian.
Croatian: Od 431 bolesnika s adenokarcinomom pankreasa koji su bili randomizirani da primaju Abraxane u kombinaciji s gemcitabinom, većina su (93%) bili bijele rase, 4% crne rase a 2% Azijati.
English: • medicines used to help you stabilize your mood also sometimes referred to as anti-depressants (e.g.
Croatian: • lijekovi koji pomažu stabilizirati raspoloženje poznati kao antidepresivi (npr. fluoksetin)
English: Febrile neutropenia occurred in four patients on Abraxane.
Croatian: Febrilna neutropenija javila se u četiri bolesnika koji su primali Abraxane.
English: Proportion of Survival both study arms treatment was administered until disease progression or development of an unacceptable toxicity.
Croatian: Udjel preživljenja obje ispitivane skupine terapija je primjenjivana do progresije bolesti ili razvoja neprihvatljive toksičnosti.
English: • if you experience numbness, tingling, pricking sensations, sensitivity to touch, or muscle weakness;
Croatian: • ako osjetite utrnulost, trnce, osjećaj bockanja, osjetljivost na dodir ili slabost u mišićima;
English: In some patients previously exposed to capecitabine, reports of palmar-plantar erythrodysaesthesiae have been reported as part of the continuing surveillance of Abraxane.
Croatian: U nekih bolesnika koji su prethodno bili izloženi kapecitabinu, zabilježena je palmarno-plantarna eritrodizestezija kao dio kontinuiranog praćenja lijeka.
English: Following Abraxane administration to patients with solid tumours, paclitaxel is evenly distributed into blood cells and plasma and is highly bound to plasma proteins (94%).
Croatian: Nakon primjene lijeka Abraxane u bolesnika sa solidnim tumorima, paklitaksel se jednoliko distribuira u krvne stanice i plazmu i u visokom se postotku veže na proteine plazme (94%).
English: Abraxane is an albumin-bound nanoparticle formulation of paclitaxel, which may have substantially different pharmacological properties compared to other formulations of paclitaxel (see sections 5.1 and 5.2).
Croatian: Abraxane je paklitaksel u obliku nanočestica vezanih za albumin koji može imati znatno drugačija farmakološka svojstva u usporedbi s drugim oblicima paklitaksela (vidjeti dijelove 5.1 i 5.2).
English: Mild to moderate renal impairment (creatinine clearance ≥30 to <90 ml/min) has no clinically important effect on the maximum elimination rate and systemic exposure (AUC and Cmax) of paclitaxel.
Croatian: Blago do umjereno oštećenje bubrežne funkcije (klirens kreatinina od ≥ 30 do < 90 ml/min) nema klinički važan učinak na maksimalnu brzinu eliminacije i sistemsku izloženost paklitakselu (AUC i Cmax).
English: Table 2: Dose modifications for neutropenia and/or thrombocytopenia at the start of a cycle or within a cycle for patients with pancreatic adenocarcinoma
Croatian: Tablica 2: Promjene doze zbog neutropenije i/ili trombocitopenije na početku ciklusa ili tijekom ciklusa u bolesnika s adenokarcinomom pankreasa Dan ciklusa
English: OTHER SPECIAL WARNING(S), IF NECESSARY Abraxane should not be substituted for or with other paclitaxel formulations.
Croatian: DRUGO(A) POSEBNO(A) UPOZORENJE(A), AKO JE POTREBNO Abraxane ne smije biti zamjena za drugi pripravak paklitaksela, niti se smije zamijeniti drugim pripravcima paklitaksela.
English: Population pharmacokinetic analysis for Abraxane included patients with ages ranging from 24 to 85 years old and shows that age does not significantly influence the maximum elimination rate and systemic exposure (AUC and Cmax) of paclitaxel.
Croatian: Analiza populacijske farmakokinetike za Abraxane uključila je bolesnike u dobi od 24 do 85 godina i pokazuje da dob ne utječe značajno na maksimalnu brzinu eliminacije i sistemsku izloženost paklitakselu (AUC i Cmax).